The PSA nadir that indicates potential cure after radiotherapy for prostate cancer
Authors:
- A. Keith LevinsonALA. Keith Levinson
- W. Hamilton WilliamsWWW. Hamilton Williams
- David A. HolladayDHDavid A. Holladay
- Clinton T. HolladayCHClinton T. Holladay
- Eric A. KleinEKEric A. Klein
- Patrick J. KupelianPKPatrick J. Kupelian
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate Cancer: The relationship between nadir level and disease-free survivalJournal of Urology, 1996
- The Periurethral Glands do not Significantly Influence the Serum Prostate Specific Antigen ConcentrationJournal of Urology, 1996
- Prostate Specific Antigen Following Radiotherapy for Local Prostate CancerJournal of Urology, 1995
- Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcomeUrology, 1995
- The Clinical Usefulness of Prostate Specific Antigen: Update 1994Journal of Urology, 1994
- PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1994
- The Value of Serial Prostate Specific Antigen Determinations 5 Years after Radiotherapy: Steeply Increasing Values Characterize 80% of PatientsJournal of Urology, 1993
- The Enhanced Detection of Persistent Disease After Prostatectomy with a New Prostate Specific Antigen ImmunoassayJournal of Urology, 1993
- The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate CancerJournal of Urology, 1993
- Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostateUrology, 1993